
New president and chief executive for EMMES
pharmafile | August 14, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | EMMES
Research support firm The EMMES Corporation has announced that its executive VP Dr Anne Lindblad has been promoted to president and chief executive.
Lindblad replaces Dr Donald Stablein at the Maryland, US-based company, who has been named past president.
“My first goal is to continue the legacy that Don and I built at EMMES,” said Lindblad. “That means maintaining our top-quality workforce and providing high-level, valued support to government, industry, foundation and university clients. In addition to our core clinical trials and research support, we have the opportunity to expand on our genomic and bioinformatics expertise and platforms.”
A biostatistician with experience in clinical design and project management, Lindblad joined EMMES in 1982 and became vice president in 1992 and executive VP in 2006. During her 30-year career at EMMES, she has led major projects in ophthalmology, oncology, nephrology, transplantation, neurology, stroke, traumatic brain injury, dental disease and swallowing disorders.
She has served as a reviewer of grant and contract applications for the National Institutes of Health and has chaired or served on Data and Safety Monitoring Committees in multiple disease areas.
In addition, she has served on the board of directors and as president of the Society for Clinical Trials, as well as the clinical trials section editor for JAMA Ophthalmology, formerly the Archives of Ophthalmology. Lindblad has authored or co-authored more than 100 publications and presentations.






